Azin Kheirkhah
Overview
Explore the profile of Azin Kheirkhah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gruber I, Kollerits B, Forer L, Di Maio S, Schachtl-Riess J, Kheirkhah A, et al.
J Intern Med
. 2024 Nov;
296(6):510-526.
PMID: 39513193
Background: Lipoprotein(a) (Lp(a)) is a causal, genetically determined risk factor for cardiovascular disease (CVD) in the general population. Patients with chronic kidney disease (CKD) have an increased CVD risk and...
2.
Barkas F, Sener Y, Golforoush P, Kheirkhah A, Rodriguez-Sanchez E, Novak J, et al.
Atherosclerosis
. 2024 Jun;
395:117579.
PMID: 38824844
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been...
3.
Pott J, Kheirkhah A, Gadin J, Kleber M, Delgado G, Kirsten H, et al.
Biol Sex Differ
. 2024 Mar;
15(1):26.
PMID: 38532495
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player of lipid metabolism with higher plasma levels in women throughout their life. Statin treatment affects PCSK9 levels also showing...
4.
Kheirkhah A, Schachtl-Riess J, Lamina C, Di Maio S, Koller A, Schonherr S, et al.
Atherosclerosis
. 2023 Nov;
386:117384.
PMID: 37989062
Background And Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid homeostasis. A few earlier genome-wide association studies (GWAS) investigated genetic variants associated with circulating PCSK9...
5.
Schachtl-Riess J, Schonherr S, Lamina C, Forer L, Coassin S, Streiter G, et al.
Atherosclerosis
. 2023 Feb;
368:1-11.
PMID: 36812656
Background And Aims: HDL-mediated cholesterol efflux capacity (CEC) may protect from cardiovascular disease. Thus, we aimed to identify its genetic and non-genetic determinants. Methods: We measured CEC to 2% apolipoprotein...
6.
Kheirkhah A, Lamina C, Kollerits B, Schachtl-Riess J, Schultheiss U, Forer L, et al.
Clin J Am Soc Nephrol
. 2022 Apr;
17(6):809-818.
PMID: 35387881
Background And Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid homeostasis. Studies investigating the association between PCSK9 and cardiovascular disease in large cohorts of patients...
7.
Schachtl-Riess J, Kheirkhah A, Gruneis R, Di Maio S, Schoenherr S, Streiter G, et al.
J Am Coll Cardiol
. 2021 Jul;
78(5):437-449.
PMID: 34325833
Background: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding...
8.
Weissensteiner H, Forer L, Fendt L, Kheirkhah A, Salas A, Kronenberg F, et al.
Genome Res
. 2021 Jan;
31(2):309-316.
PMID: 33452015
Within-species contamination is a major issue in sequencing studies, especially for mitochondrial studies. Contamination can be detected by analyzing the nuclear genome or by inspecting polymorphic sites in the mitochondrial...
9.
Kheirkhah A, Lamina C, Rantner B, Kollerits B, Stadler M, Pohlhammer J, et al.
Atherosclerosis
. 2020 Dec;
316:41-47.
PMID: 33302043
Background And Aims: Peripheral artery disease (PAD) affects more than 200 million people worldwide. Increased low-density lipoprotein cholesterol (LDL-C)levels are a risk factor for PAD and the concentrations are influenced...